JP2009536201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536201A5 JP2009536201A5 JP2009509615A JP2009509615A JP2009536201A5 JP 2009536201 A5 JP2009536201 A5 JP 2009536201A5 JP 2009509615 A JP2009509615 A JP 2009509615A JP 2009509615 A JP2009509615 A JP 2009509615A JP 2009536201 A5 JP2009536201 A5 JP 2009536201A5
- Authority
- JP
- Japan
- Prior art keywords
- rage
- formulation
- fusion protein
- seq
- reconstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 238000009472 formulation Methods 0.000 claims 36
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- 102000002110 C2 domains Human genes 0.000 claims 3
- 108050009459 C2 domains Proteins 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79845506P | 2006-05-05 | 2006-05-05 | |
| US60/798,455 | 2006-05-05 | ||
| PCT/US2007/010125 WO2007130302A2 (en) | 2006-05-05 | 2007-04-25 | Rage fusion proteins, formulations, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536201A JP2009536201A (ja) | 2009-10-08 |
| JP2009536201A5 true JP2009536201A5 (OSRAM) | 2010-06-17 |
| JP5558810B2 JP5558810B2 (ja) | 2014-07-23 |
Family
ID=38521887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009509615A Expired - Fee Related JP5558810B2 (ja) | 2006-05-05 | 2007-04-25 | Ｒａｇｅ融合タンパク質、製剤及びその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7981424B2 (OSRAM) |
| EP (2) | EP2380983A3 (OSRAM) |
| JP (1) | JP5558810B2 (OSRAM) |
| KR (1) | KR20090008459A (OSRAM) |
| CN (1) | CN101548012A (OSRAM) |
| AR (1) | AR060862A1 (OSRAM) |
| AU (1) | AU2007248784B2 (OSRAM) |
| BR (1) | BRPI0711193A2 (OSRAM) |
| CA (1) | CA2651348A1 (OSRAM) |
| DO (1) | DOP2007000089A (OSRAM) |
| EA (1) | EA017291B1 (OSRAM) |
| IL (1) | IL194482A0 (OSRAM) |
| MX (1) | MX2008013863A (OSRAM) |
| NL (1) | NL2000626A1 (OSRAM) |
| NZ (1) | NZ571692A (OSRAM) |
| PE (1) | PE20080397A1 (OSRAM) |
| SG (1) | SG171670A1 (OSRAM) |
| TW (1) | TW200801036A (OSRAM) |
| UY (1) | UY30324A1 (OSRAM) |
| WO (1) | WO2007130302A2 (OSRAM) |
| ZA (1) | ZA200809394B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
| EP1781700B1 (en) | 2004-08-03 | 2014-03-19 | TransTech Pharma, LLC | Rage fusion proteins and methods of use |
| RU2431804C2 (ru) * | 2005-12-23 | 2011-10-20 | ДжиКоудер Системз АБ | Шаблон позиционирования |
| AU2007215503A1 (en) * | 2006-02-09 | 2007-08-23 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| WO2007130302A2 (en) | 2006-05-05 | 2007-11-15 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
| US20100216977A1 (en) * | 2007-02-15 | 2010-08-26 | Kyushu University, National University Corporation | Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody |
| WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| WO2008099913A1 (ja) | 2007-02-15 | 2008-08-21 | Kumamoto University | ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 |
| US20100173277A1 (en) * | 2007-02-15 | 2010-07-08 | Fukuoka University | Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody |
| KR101595634B1 (ko) | 2007-06-14 | 2016-02-18 | 갈락티카 파마슈티칼스, 인크. | Ｒａｇｅ 융합 단백질 |
| EP2421892A1 (en) * | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
| WO2013074820A1 (en) | 2011-11-16 | 2013-05-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immunogenic tumor associated stromal cell antigen peptides and methods of their use |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| HUE043820T2 (hu) * | 2012-11-28 | 2019-09-30 | Nono Inc | Liofilizált TAT-NR2B9c készítmény |
| EP3633381A3 (en) | 2013-12-05 | 2020-07-29 | The Broad Institute, Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
| JP6617110B2 (ja) * | 2014-10-01 | 2019-12-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | 遺伝子組換えカイコにより生産したビオチン化酸化ｌｄｌ受容体・終末糖化産物受容体 |
| EP3307781B8 (en) | 2015-06-10 | 2020-12-02 | The Broad Institute, Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
| EP3389715A4 (en) | 2015-12-14 | 2019-06-12 | David K. Thomas | COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION |
| CN112699601B (zh) * | 2020-12-28 | 2022-05-31 | 电子科技大学 | 一种传感器网络数据的空时重构方法 |
| US20230246158A1 (en) * | 2022-02-02 | 2023-08-03 | Enevate Corporation | Cycle life in si/li batteries using high temperature deep discharge cycling |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| EP0672141B1 (en) | 1992-10-23 | 2003-05-14 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| EP1327887A3 (en) | 1995-01-18 | 2008-12-10 | Synvista Therapeutics, Inc. | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products |
| NO315930B1 (no) | 1995-01-18 | 2003-11-17 | Picower Inst For Medical Res T | Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser |
| US5656261A (en) | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
| JPH11504316A (ja) | 1995-04-05 | 1999-04-20 | ザ ピコワー インスティテュート フォア メディカル リサーチ | 進行性グリコシル化終末産物に結合する薬剤及びその使用方法 |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AU1832797A (en) | 1996-01-26 | 1997-08-20 | Trustees Of Columbia University In The City Of New York, The | A polypeptide from lung extract which binds amyloid-beta peptide |
| AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US7081241B1 (en) | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| WO1998040071A1 (en) | 1997-03-11 | 1998-09-17 | The General Hospital Corporation | Identification of agents for use in the treatment of alzheimer's disease |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| MY131805A (en) | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
| US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US6706683B1 (en) | 1998-09-29 | 2004-03-16 | Asahi Kasei Pharma Corporation | Method for controlling the release of granules |
| PL202399B1 (pl) * | 1998-10-05 | 2009-06-30 | Pharmexa As | Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an |
| US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| HK1041293B (en) | 1998-10-06 | 2008-01-25 | The Trustees Of Columbia University In The City Of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
| US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| US6605642B2 (en) | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
| US6589944B1 (en) | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
| US6787566B2 (en) | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
| FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| EP1307219A4 (en) | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| WO2001018060A1 (fr) | 1999-09-08 | 2001-03-15 | Toray Industries, Inc. | Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique |
| US20050170382A1 (en) | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
| EP1287162A2 (en) | 1999-10-21 | 2003-03-05 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
| CA2382165A1 (en) | 1999-12-08 | 2001-06-14 | Genset S.A. | Full-length human cdnas encoding potentially secreted proteins |
| DE60129008T2 (de) | 2000-04-14 | 2007-10-11 | Niadyne Corp., Tucson | Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten |
| AU2001255436A1 (en) | 2000-04-17 | 2001-10-30 | Transtech Pharma | Protein expression system arrays and use in biological screening |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| US6563015B1 (en) | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
| EA200300442A1 (ru) | 2000-10-02 | 2003-10-30 | Редди Ю Эс Терапьютикс, Инк. | Способы и композиции для лечения воспалительных заболеваний |
| AU2002213192A1 (en) | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
| US20050244849A1 (en) | 2000-12-15 | 2005-11-03 | Genetics Institute, Llc | Screening assays for rheumatoid arthritis |
| PL366250A1 (en) | 2000-12-29 | 2005-01-24 | Reddy Us Therapeutics, Inc. | Detection of compounds that modulate inflammatory responses |
| KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
| JP3837494B2 (ja) | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| JP2006512900A (ja) * | 2002-08-16 | 2006-04-20 | ワイス | Ｒａｇｅ関連疾患の治療用組成物及び方法 |
| WO2004100890A2 (en) | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
| US20050008649A1 (en) | 2003-06-02 | 2005-01-13 | University Of Miami | Chimeric molecules and methods of use |
| ZA200601810B (en) | 2003-09-05 | 2008-05-28 | Univ Columbia | Rage-related methods and compositions for treating glomerular injury |
| WO2005042032A1 (en) | 2003-10-31 | 2005-05-12 | The Trustees Of Columbia University In The City Of New York | Methods for treating multiple sclerosis |
| US20060012414A1 (en) * | 2004-07-15 | 2006-01-19 | Texas Instruments Incorporated | Circuit and method for generating a polyphase clock signal and system incorporating the same |
| EP1771565B1 (en) * | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| US20060040354A1 (en) | 2004-07-20 | 2006-02-23 | O'keefe Theresa L | Novel polyadenylation signal for use in expression vectors |
| US20060078562A1 (en) | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
| EP1781700B1 (en) * | 2004-08-03 | 2014-03-19 | TransTech Pharma, LLC | Rage fusion proteins and methods of use |
| CA2581505A1 (en) | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| US20080207499A1 (en) | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
| AU2007215503A1 (en) | 2006-02-09 | 2007-08-23 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| WO2007130302A2 (en) | 2006-05-05 | 2007-11-15 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
| WO2008100470A2 (en) | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
-
2007
- 2007-04-25 WO PCT/US2007/010125 patent/WO2007130302A2/en not_active Ceased
- 2007-04-25 EP EP11167432A patent/EP2380983A3/en not_active Withdrawn
- 2007-04-25 NZ NZ571692A patent/NZ571692A/en not_active IP Right Cessation
- 2007-04-25 MX MX2008013863A patent/MX2008013863A/es active IP Right Grant
- 2007-04-25 CA CA002651348A patent/CA2651348A1/en not_active Abandoned
- 2007-04-25 SG SG201103296-8A patent/SG171670A1/en unknown
- 2007-04-25 CN CNA200780018207XA patent/CN101548012A/zh active Pending
- 2007-04-25 KR KR1020087029731A patent/KR20090008459A/ko not_active Withdrawn
- 2007-04-25 EP EP07794379A patent/EP2021474A2/en not_active Withdrawn
- 2007-04-25 JP JP2009509615A patent/JP5558810B2/ja not_active Expired - Fee Related
- 2007-04-25 BR BRPI0711193-2A patent/BRPI0711193A2/pt not_active IP Right Cessation
- 2007-04-25 US US11/789,637 patent/US7981424B2/en not_active Expired - Fee Related
- 2007-04-25 EA EA200870502A patent/EA017291B1/ru not_active IP Right Cessation
- 2007-04-25 AU AU2007248784A patent/AU2007248784B2/en not_active Ceased
- 2007-05-04 PE PE2007000550A patent/PE20080397A1/es not_active Application Discontinuation
- 2007-05-04 UY UY30324A patent/UY30324A1/es not_active Application Discontinuation
- 2007-05-04 AR ARP070101949A patent/AR060862A1/es not_active Application Discontinuation
- 2007-05-04 DO DO2007000089A patent/DOP2007000089A/es unknown
- 2007-05-04 TW TW096115905A patent/TW200801036A/zh unknown
- 2007-05-04 NL NL2000626A patent/NL2000626A1/nl not_active IP Right Cessation
-
2008
- 2008-10-02 IL IL194482A patent/IL194482A0/en unknown
- 2008-11-03 ZA ZA200809394A patent/ZA200809394B/xx unknown
-
2011
- 2011-06-13 US US13/158,748 patent/US8344120B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536201A5 (OSRAM) | ||
| US20230060574A1 (en) | Serum albumin binders | |
| JP7417421B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| AU2018209150B2 (en) | Improved serum albumin binders | |
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| JP2016534052A5 (OSRAM) | ||
| JP2021504372A5 (OSRAM) | ||
| KR20180100439A (ko) | 이중특이적 항체 작제물을 포함하는 약제학적 조성물 | |
| KR20170010893A (ko) | 아미노 말단 면역글로불린 융합 단백질 및 이의 조성물을 구축하는 방법 | |
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| KR20230058432A (ko) | 약제학적 제형 | |
| CN112390884B (zh) | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 | |
| HK40117444A (en) | Improved serum albumin binders | |
| HK40118030A (en) | Improved serum albumin binders | |
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| HK40116819A (en) | Improved serum albumin binders | |
| HK40119626A (en) | Improved serum albumin binders | |
| HK40017968A (en) | Improved serum albumin binders | |
| CN111902189A (zh) | 用于治疗儿科患者中的癌症的雷莫芦单抗 | |
| HK40018516A (en) | Improved serum albumin binders | |
| HK40018516B (en) | Improved serum albumin binders |